Literature DB >> 9578814

Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine.

E Modigliani1, R Cohen, J M Campos, B Conte-Devolx, B Maes, A Boneu, M Schlumberger, J C Bigorgne, P Dumontier, L Leclerc, B Corcuff, I Guilhem.   

Abstract

BACKGROUND: Prognostic factors of sporadic or inherited medullary thyroid carcinoma (MTC) are still controversial and have been assessed in old and small series. A better knowledge of these factors would improve patient management.
OBJECTIVE: To evaluate factors involved in the prognosis of MTC in a large series of cases, using uni- and multivariate analysis. DESIGN AND PATIENTS: Clinical, biological, surgical and epidemiological data on 899 MTC patients, diagnosed between 1952 and 1996, were collected by the French Calcitonin Tumors Study Group (GETC) with a standardized questionnaire, and processed in a national database. MEASUREMENTS: Survival and biochemical cure (i.e. normal basal post-operative serum calcitonin levels) were analysed with Kaplan and Meier and log-rank test statistical procedures. Data are presented as adjusted rather than observed survival, to consider only patients who died of MTC. Cox's forward-stepping proportional hazard model was used to analyse factors with a significant influence on survival by univariate analysis.
RESULTS: Apart from the large proportion of familial forms (43%), the general characteristics of our population were similar to those in other studies: mean age at surgery = 43.4 years; sex ratio = 1 male/1.35 female; stage I = 20.8%; stage II = 21.2%; stage III = 46.5% and stage IV = 11.5%. 863 (96%) patients underwent surgery; 43% of operated patients were biochemically cured. Adjusted survival was 85.7 +/- 1.5% at 5 years and 78.4 +/- 2.1% at 10 years. Multivariate analysis showed that age and stage were independent predictive factors of survival. Gender, type of surgery, type of familial form were predictive only in univariate analysis. Biochemical cure predicts a survival rate of 97.7% at 10 years. Authentic recurrence, that is subsequent elevation of calcitonin (CT) after post-operative normalization, was found in 4.9%. In non-cured patients (57%), survival was still good: 80.2% (+/- 2.2%) and 70.3% (+/- 2.9%) at 5 and 10 years, respectively. Similarly, prediction of biochemical cure was solely dependent on stage.
CONCLUSION: Survival of these medullary thyroid carcinoma patients appears better than expected even in non-cured patients. Considering the strong impact of stage, the necessity for pre-operative diagnosis of MTC is obvious.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9578814     DOI: 10.1046/j.1365-2265.1998.00392.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  109 in total

1.  Postoperative Nomogram for Predicting Cancer-Specific Mortality in Medullary Thyroid Cancer.

Authors:  Allen S Ho; Lu Wang; Frank L Palmer; Changhong Yu; Arnbjorn Toset; Snehal Patel; Michael W Kattan; R Michael Tuttle; Ian Ganly
Journal:  Ann Surg Oncol       Date:  2014-11-04       Impact factor: 5.344

2.  Adjuvant external beam radiation for medullary thyroid carcinoma.

Authors:  Steve R Martinez; Shannon H Beal; Allen Chen; Steven L Chen; Philip D Schneider
Journal:  J Surg Oncol       Date:  2010-08-01       Impact factor: 3.454

Review 3.  Thyroid and aging.

Authors:  Mouhammed Habra; Nicholas J Sarlis
Journal:  Rev Endocr Metab Disord       Date:  2005-05       Impact factor: 6.514

4.  Prognostic factors for sporadic medullary thyroid carcinoma.

Authors:  Kaptan Gülben; Uğur Berberoğlu; Mustafa Boyabatli
Journal:  World J Surg       Date:  2006-01       Impact factor: 3.352

5.  Long-term outcome of reoperations for medullary thyroid carcinoma.

Authors:  Elizabeth Fialkowski; Mary DeBenedetti; Jeffrey Moley
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

Review 6.  Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls.

Authors:  Giuseppe Costante; Cosimo Durante; Zélia Francis; Martin Schlumberger; Sebastiano Filetti
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2009-01

7.  Medullary thyroid cancer, papillary thyroid microcarcinoma and Graves' disease: an unusual clinical coexistence.

Authors:  G Mazziotti; M Rotondi; G Manganella; R Franco; V Colantuoni; G Amato; C Carella
Journal:  J Endocrinol Invest       Date:  2001-12       Impact factor: 4.256

8.  (68)Ga-somatostatin analogues PET and (18)F-DOPA PET in medullary thyroid carcinoma.

Authors:  Valentina Ambrosini; Maria Cristina Marzola; Domenico Rubello; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

9.  Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma.

Authors:  Jian Yu Xu; William A Murphy; Denái R Milton; Camilo Jimenez; Sarika N Rao; Mouhammed Amir Habra; Steven G Waguespack; Ramona Dadu; Robert F Gagel; Anita K Ying; Maria E Cabanillas; Steven P Weitzman; Naifa L Busaidy; Rena V Sellin; Elizabeth Grubbs; Steven I Sherman; Mimi I Hu
Journal:  J Clin Endocrinol Metab       Date:  2016-09-23       Impact factor: 5.958

10.  Prognostic influence of clinical and pathological factors in medullary thyroid carcinoma: a study of 53 cases.

Authors:  Lenine G Brandão; Beatriz G Cavalheiro; Consuelo R Junqueira
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.